These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 28861920)

  • 21. p53 major hotspot variants are associated with poorer prognostic features in hereditary cancer patients.
    Fortuno C; Pesaran T; Dolinsky J; Yussuf A; McGoldrick K; Kho PF; James PA; Spurdle AB
    Cancer Genet; 2019 Jun; 235-236():21-27. PubMed ID: 31296311
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Revisiting tumor patterns and penetrance in germline TP53 mutation carriers: temporal phases of Li-Fraumeni syndrome.
    Amadou A; Achatz MIW; Hainaut P
    Curr Opin Oncol; 2018 Jan; 30(1):23-29. PubMed ID: 29076966
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Two TP53 germline mutations in a classical Li-Fraumeni syndrome family.
    van Hest LP; Ruijs MW; Wagner A; van der Meer CA; Verhoef S; van't Veer LJ; Meijers-Heijboer H
    Fam Cancer; 2007; 6(3):311-6. PubMed ID: 17318340
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Penetrance Estimates Over Time to First and Second Primary Cancer Diagnosis in Families with Li-Fraumeni Syndrome: A Single Institution Perspective.
    Shin SJ; Dodd-Eaton EB; Gao F; Bojadzieva J; Chen J; Kong X; Amos CI; Ning J; Strong LC; Wang W
    Cancer Res; 2020 Jan; 80(2):347-353. PubMed ID: 31719099
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multiple primary tumors in a family with Li-Fraumeni syndrome with a TP53 germline mutation identified by next-generation sequencing.
    Zampiga V; Danesi R; Tedaldi G; Tebaldi M; Cangini I; Pirini F; Pittureri C; Amaducci E; Guidi L; Faedi M; Amadori D; Falcini F; Calistri D
    Int J Biol Markers; 2016 Dec; 31(4):e461-e465. PubMed ID: 27516001
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The profile and contribution of rare germline copy number variants to cancer risk in Li-Fraumeni patients negative for TP53 mutations.
    Silva AG; Krepischi AC; Pearson PL; Hainaut P; Rosenberg C; Achatz MI
    Orphanet J Rare Dis; 2014 Apr; 9():63. PubMed ID: 24775443
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multiple Germline Events Contribute to Cancer Development in Patients with Li-Fraumeni Syndrome.
    Subasri V; Light N; Kanwar N; Brzezinski J; Luo P; Hansford JR; Cairney E; Portwine C; Elser C; Finlay JL; Nichols KE; Alon N; Brunga L; Anson J; Kohlmann W; de Andrade KC; Khincha PP; Savage SA; Schiffman JD; Weksberg R; Pugh TJ; Villani A; Shlien A; Goldenberg A; Malkin D
    Cancer Res Commun; 2023 May; 3(5):738-754. PubMed ID: 37377903
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Li-Fraumeni syndrome in Tunisian carriers with different and rare tumor phenotype: genotype-phenotype correlation.
    Sassi H; Meddeb R; Cherif MA; Nasr C; Riahi A; Hannachi S; Belguith N; M'rad R
    BMC Med Genomics; 2022 Mar; 15(1):44. PubMed ID: 35246108
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence of germline mutations in the TP53 gene in patients with early-onset breast cancer in the Mexican population.
    Gallardo-Alvarado LN; Tusié-Luna MT; Tussié-Luna MI; Díaz-Chávez J; Segura YX; Bargallo-Rocha E; Villarreal C; Herrera-Montalvo LA; Herrera-Medina EM; Cantu-de Leon DF
    BMC Cancer; 2019 Feb; 19(1):118. PubMed ID: 30709381
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association between Predicted Effects of
    Liu Y; Axell O; van Leeuwen T; Konrat R; Kharaziha P; Larsson C; Wright APH; Bajalica-Lagercrantz S
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34198491
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Paired Tumor-Normal Sequencing Provides Insights Into the TP53-Related Cancer Spectrum in Patients With Li-Fraumeni Syndrome.
    Ceyhan-Birsoy O; Selenica P; Chui MH; Jayakumaran G; Ptashkin R; Misyura M; Aypar U; Jairam S; Yang C; Li Y; Mehta N; Kemel Y; Salo-Mullen E; Maio A; Sheehan M; Zehir A; Carlo M; Latham A; Stadler Z; Robson M; Offit K; Ladanyi M; Walsh M; Reis-Filho JS; Mandelker D
    J Natl Cancer Inst; 2021 Nov; 113(12):1751-1760. PubMed ID: 34240179
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MIR605 rs2043556 is associated with the occurrence of multiple primary tumors in TP53 p.(Arg337His) mutation carriers.
    Bandeira IC; Vieira IA; Andreis TF; Brussa Reis L; Macedo GS; Vianna FSL; Santos-Silva P; Palmero EI; Galvão HCR; Ramos CRN; Santiago KM; Achatz MI; da Costa AABA; Ashton-Prolla P
    Cancer Genet; 2020 Jan; 240():54-58. PubMed ID: 31778928
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Germline TP53 mutations and the changing landscape of Li-Fraumeni syndrome.
    Kamihara J; Rana HQ; Garber JE
    Hum Mutat; 2014 Jun; 35(6):654-62. PubMed ID: 24706533
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Super-Transactivation TP53 Variant in the Germline of a Family with Li-Fraumeni Syndrome.
    Id Said B; Kim H; Tran J; Novokmet A; Malkin D
    Hum Mutat; 2016 Sep; 37(9):889-92. PubMed ID: 27297285
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype.
    Olivier M; Goldgar DE; Sodha N; Ohgaki H; Kleihues P; Hainaut P; Eeles RA
    Cancer Res; 2003 Oct; 63(20):6643-50. PubMed ID: 14583457
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The TP53 gene promoter is not methylated in families suggestive of Li-Fraumeni syndrome with no germline TP53 mutations.
    Finkova A; Vazna A; Hrachovina O; Bendova S; Prochazkova K; Sedlacek Z
    Cancer Genet Cytogenet; 2009 Aug; 193(1):63-6. PubMed ID: 19602465
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Population-based estimate of the contribution of TP53 mutations to subgroups of early-onset breast cancer: Australian Breast Cancer Family Study.
    Mouchawar J; Korch C; Byers T; Pitts TM; Li E; McCredie MR; Giles GG; Hopper JL; Southey MC
    Cancer Res; 2010 Jun; 70(12):4795-800. PubMed ID: 20501846
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Functional evaluation of germline TP53 variants identified in Brazilian families at-risk for Li-Fraumeni syndrome.
    Abreu RBV; Pereira AS; Rosa MN; Ashton-Prolla P; Silva VAO; Melendez ME; Palmero EI
    Sci Rep; 2024 Jul; 14(1):17187. PubMed ID: 39060302
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cancer Risks Associated With
    Fortuno C; Feng BJ; Carroll C; Innella G; Kohlmann W; Lázaro C; Brunet J; Feliubadaló L; Iglesias S; Menéndez M; Teulé A; Ballinger ML; Thomas DM; Campbell A; Field M; Harris M; Kirk J; Pachter N; Poplawski N; Susman R; Tucker K; Wallis M; Williams R; Cops E; Goldgar D; ; James PA; Spurdle AB
    JCO Precis Oncol; 2024 Feb; 8():e2300453. PubMed ID: 38412388
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TP53 variants of uncertain significance: increasing challenges in variant interpretation and genetic counseling.
    Bittar CM; Vieira IA; Sabato CS; Andreis TF; Alemar B; Artigalás O; Galvão HCR; Macedo GS; Palmero EI; Ashton-Prolla P
    Fam Cancer; 2019 Oct; 18(4):451-456. PubMed ID: 31321604
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.